NPM1 and acute myeloid leukemia: Therefore, although most relapses in NPM1-mutated AML patients are due to the reappearance of the original NPM1-mutated clone, nearly 5–10% of AML recurrences are characterized by the absence of NPM1 mutations, preferably suggesting that a second de novo or therapy-related AML with NPM1 wild-type could raise from persistent clonal hematopoiesis, after the eradication of the original NPM1-mutated AML clone [5,18,121,122,123].